Product Reports Resources Pricing Login Book a demo

Loxo Oncology

Biotech & Life Sciences · Stamford, United States · Founded 2013 · IPO 2014

Loxo Oncology, a subsidiary of Eli Lilly and Company, focuses on the discovery and development of highly selective medicines aimed at treating genetically defined cancers. The company operates in the biotechnology and pharmaceutical sectors, targeting patients with specific genetic mutations that drive their cancer. Loxo Oncology's business model revolves around extensive research and development (R&D) to create a pipeline of targeted therapies, which are then brought to market through clinical trials and regulatory approvals. Revenue is generated primarily through the sale of these specialized cancer treatments, as well as potential partnerships and collaborations with other biotech firms and research institutions. The company serves oncologists and healthcare providers who treat cancer patients, particularly those with rare or hard-to-treat genetic profiles. Loxo Oncology's market includes both domestic and international healthcare sectors, with a strong emphasis on innovation and precision medicine. Keywords: oncology, genetically defined cancers, selective medicines, biotechnology, pharmaceutical, clinical trials, targeted therapies, precision medicine, Eli Lilly, cancer treatment.

Valuation $8.00B
Revenue $38M
Headcount 100–500
Total funding $50–100M
Power Law Unicorn$1–10B valuation tier Colt$25–100M revenue
Featured in
News Treeline Biosciences goes public via $460M reverse acquisition of Standard BioTools Jun 8, 2026 News Lilly buys Centessa for up to $7.8B to build neuroscience pipeline beyond obesity Apr 1, 2026

Investors

4 investors on Loxo Oncology's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 3 investors entered at this stage
Aisling Capital
OrbiMed
NEA
Series B+ 1 investor entered at this stage
NEA

Global footprint

Where Loxo Oncology has talent and traffic

Workforce by country
4 countries with
team presence
🇺🇸 United States98.3%
🇳🇱 Netherlands0.6%
🇧🇩 Bangladesh0.6%
🇺🇦 Ukraine0.6%
4 countries shown
Web traffic by country
50 monthly visits
across markets
🇺🇸 United States3400%
🇮🇳 India400%
Top 2 markets shown

Talent graph

The shape of Loxo Oncology's talent

Dealroom maps Loxo Oncology's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

7 standout operatorsDealroom-flagged across the org
1 AI specialistincl. 1 core researchers
240 employees mappedperson by person
DimensionScore
AI Talentlive Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Loxo Oncology's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$141M patent portfolio · 44 active families

Estimated portfolio value
$141M
1.8% of market cap · comparable to top peer Bicycle Therapeutics ($117M)
44 active patent families
Where Loxo Oncology innovates CarcinosisDiseaseKinase inhibitionLeukemiaMolecular biology

Where Loxo Oncology concentrates vs peers

Each axis is a top-10 topic across Loxo Oncology and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Loxo Oncology

An AI-synthesized read of the highest-engagement posts about Loxo Oncology on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Loxo Oncology on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles